ClinicalTrials.gg
CompletedNCT01844531Updated Jul 27, 2015Results posted

Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets

A Phase 1 interventional study of empagliflozin and metformin (Glucophage®) in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-27.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The primary objective of this trial is to establish bioequivalence of two fixed dose combination (FDC) tablets (containing medium dose empagliflozin/500 mg metformin [Test 1] and low dose empagliflozin/500 mg metformin [Test 2]) and of the single tablets (medium dose empagliflozin tablets + Glucophage® 500 mg tablet [Reference 1] and low dose empagliflozin tablet + Glucophage® 500 mg tablet [Reference 2]) when administered together after a high fat, high caloric meal.

The assessment of safety and tolerability will be an additional objective of this trial.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects
  2. Subjects must be able to understand and comply with study requirements
  3. Age 18 to 50 years
  4. (BMI) 18.5 to 29.9 kg/m2

Exclusion criteria

Exclusion criteria:

  1. Any relevant deviation from healthy conditions
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    FDC empagliflozin dose 1 and metformin

    fix dose combination tablet after intake of a high fat, high caloric meal

    Drug: empagliflozin and metformin

  • Active comparator
    empagliflozin dose 1 + metformin tablets

    single tablets after intake of a high fat, high caloric meal

    Drug: empagliflozin · Drug: metformin (Glucophage®)

  • Experimental
    FDC empagliflozin dose 2 and metformin

    fix dose combination tablet after intake of a high fat, high caloric meal

    Drug: empagliflozin and metformin

  • Active comparator
    empagliflozin dose 2 + metformin tablets

    single tablets after intake of a high fat, high caloric meal

    Drug: metformin (Glucophage®) · Drug: empagliflozin

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-∞ for Empagliflozin

    AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Empagliflozin

    Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake

  2. AUC0-∞ for Metformin

    AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin

    Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake

  3. Cmax for Empagliflozin

    Cmax (maximum measured concentration of the analyte in plasma) for Empagliflozin

    Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake

  4. Cmax for Metformin

    Cmax (maximum measured concentration of the analyte in plasma) for Metformin

    Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake

Secondary outcomes

  1. AUC0-tz for Empagliflozin

    AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Empagliflozin

    Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake

  2. AUC0-tz for Metformin

    AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Metformin

    Time frame: 1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake

07

Results

Posted Jul 27, 2015

Participant flow

Participant flow — Overall Study
MilestoneFDC Empa12.5/ Empa12.5+Met500/ FDC Empa5/ Empa5+Met500Empa12.5+Met500/ FDC Empa12.5/ Empa5+Met500/ FDC Empa5FDC Empa5/ Empa5+Met500/ FDC Empa12.5/ Empa12.5+Met500Empa5+Met500/ FDC Empa5/ Empa12.5+Met500/ FDC Empa12.5
Started6666
Completed6566
Not completed0100
Withdrew: Withdrawal by subject0100

Outcome measures

PrimaryAUC0-∞ for Empagliflozin

AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Empagliflozin

Time frame:
1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
Reported as:
Geometric mean · nmol*h/L
AUC0-∞ for Empagliflozin
nmol*h/L12.5 mg Empagliflozin and 500 mg Metformin as FDC12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets5 mg Empagliflozin and 500 mg Metformin as FDC5 mg Empagliflozin and 500 mg Metformin as Single Tablets
AUC0-∞ for Empagliflozin2780 ± 16.12870 ± 17.31110 ± 15.71070 ± 19.2
Statistical analysis
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0000 (Model included effects:sequence;subjects within sequences;period and treatment with subjects within sequences as random effect.) · Adjusted gmean ratio fdc/single tablets: 97.92 · 90% CI 93.529 to 102.520\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = <.0001 (Model included effects:sequence;subjects within sequences;period and treatment with all effects as fixed.) · Adjusted gmean ratio fdc/single tablets: 98.00 · 90% CI 93.57 to 102.65\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0000 (Model included effects:sequence;subjects within sequences;period and treatment with subjects within sequences as random effect.) · Adjusted gmean ratio fdc/single tablets: 102.79 · 90% CI 99.077 to 106.633\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = <.0001 · Adjusted gmean ratio fdc/single tablets: 102.50 · 90% CI 98.78 to 106.36\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
PrimaryAUC0-∞ for Metformin

AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity) for Metformin

Time frame:
1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
Reported as:
Geometric mean · ng*h/mL
AUC0-∞ for Metformin
ng*h/mL12.5 mg Empagliflozin and 500 mg Metformin as FDC12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets5 mg Empagliflozin and 500 mg Metformin as FDC5 mg Empagliflozin and 500 mg Metformin as Single Tablets
AUC0-∞ for Metformin5590 ± 19.05820 ± 21.85960 ± 18.06190 ± 19.5
Statistical analysis
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0006 · Adjusted gmean ratio fdc/single tablets: 96.25 · 90% CI 88.542 to 104.628\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0004 · Adjusted gmean ratio fdc/single tablets: 97.21 · 90% CI 89.41 to 105.68\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0000 · Adjusted gmean ratio fdc/single tablets: 96.79 · 90% CI 91.772 to 102.093\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = <.0001 · Adjusted gmean ratio fdc/single tablets: 96.91 · 90% CI 91.79 to 102.32\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
SecondaryAUC0-tz for Empagliflozin

AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Empagliflozin

Time frame:
1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
Reported as:
Geometric mean · nmol*h/L
AUC0-tz for Empagliflozin
nmol*h/L12.5 mg Empagliflozin and 500 mg Metformin as FDC12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets5 mg Empagliflozin and 500 mg Metformin as FDC5 mg Empagliflozin and 500 mg Metformin as Single Tablets
AUC0-tz for Empagliflozin2740 ± 16.32830 ± 17.31080 ± 15.71040 ± 19.1
Statistical analysis
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0000 · Adjusted gmean ratio fdc/single tablets: 98.00 · 90% CI 93.530 to 102.686\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = <.0001 · Adjusted gmean ratio fdc/single tablets: 98.07 · 90% CI 93.55 to 102.81\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0000 · Adjusted gmean ratio fdc/single tablets: 102.77 · 90% CI 99.146 to 106.522\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = <.0001 · Adjusted gmean ratio fdc/single tablets: 102.49 · 90% CI 98.85 to 106.25\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
PrimaryCmax for Empagliflozin

Cmax (maximum measured concentration of the analyte in plasma) for Empagliflozin

Time frame:
1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
Reported as:
Geometric mean · nmol/L
Cmax for Empagliflozin
nmol/L12.5 mg Empagliflozin and 500 mg Metformin as FDC12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets5 mg Empagliflozin and 500 mg Metformin as FDC5 mg Empagliflozin and 500 mg Metformin as Single Tablets
Cmax for Empagliflozin294 ± 23.7282 ± 27.4109 ± 22.8106 ± 22.5
Statistical analysis
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0000 · Adjusted gmean ratio fdc/single tablets: 104.61 · 90% CI 99.882 to 109.555\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = <.0001 · Adjusted gmean ratio fdc/single tablets: 104.53 · 90% CI 99.76 to 109.53\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0000 · Adjusted gmean ratio fdc/single tablets: 102.96 · 90% CI 97.917 to 108.258\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = <.0001 · Adjusted gmean ratio fdc/single tablets: 102.80 · 90% CI 97.72 to 108.14\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
PrimaryCmax for Metformin

Cmax (maximum measured concentration of the analyte in plasma) for Metformin

Time frame:
1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
Reported as:
Geometric mean · ng/mL
Cmax for Metformin
ng/mL12.5 mg Empagliflozin and 500 mg Metformin as FDC12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets5 mg Empagliflozin and 500 mg Metformin as FDC5 mg Empagliflozin and 500 mg Metformin as Single Tablets
Cmax for Metformin686 ± 14.1718 ± 19.7693 ± 12.8743 ± 19.6
Statistical analysis
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0001 · Adjusted gmean ratio fdc/single tablets: 94.76 · 90% CI 89.056 to 100.819\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0001 · Adjusted gmean ratio fdc/single tablets: 94.40 · 90% CI 88.64 to 100.54\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0002 · Adjusted gmean ratio fdc/single tablets: 93.83 · 90% CI 88.006 to 100.034\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0003 · Adjusted gmean ratio fdc/single tablets: 93.98 · 90% CI 87.94 to 100.43\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
SecondaryAUC0-tz for Metformin

AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point) for Metformin

Time frame:
1hour (h) before drug intake and 20minutes (min),40min,1h,1h 30min,2h,2h 30min, 3h, 3h 30min, 4h, 5h, 6h, 8h,10h,12h,24h,34h,48h,72h after drug intake
Reported as:
Geometric mean · ng*h/mL
AUC0-tz for Metformin
ng*h/mL12.5 mg Empagliflozin and 500 mg Metformin as FDC12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets5 mg Empagliflozin and 500 mg Metformin as FDC5 mg Empagliflozin and 500 mg Metformin as Single Tablets
AUC0-tz for Metformin5480 ± 18.95720 ± 21.25820 ± 17.76110 ± 19.2
Statistical analysis
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0008 · Adjusted gmean ratio fdc/single tablets: 95.78 · 90% CI 88.000 to 104.256\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 12.5 mg Empagliflozin and 500 mg Metformin as FDC vs 12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0006 · Adjusted gmean ratio fdc/single tablets: 96.74 · 90% CI 88.78 to 105.41\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = 0.0000 · Adjusted gmean ratio fdc/single tablets: 95.94 · 90% CI 91.199 to 100.934\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].
  • 5 mg Empagliflozin and 500 mg Metformin as FDC vs 5 mg Empagliflozin and 500 mg Metformin as Single Tablets · ANOVA · p = <.0001 · Adjusted gmean ratio fdc/single tablets: 96.10 · 90% CI 91.28 to 101.19\*Results reported as Standard Error of the mean are Intra-individual geometric coefficient of variation \[%\].

Adverse events

Collected over From study drug administration of 1 treatment period until study drug administration in the next treatment period or date of trial completion plus 1 day, up to 8 days (and up to 16 days for one subject only). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
12.5 mg Empagliflozin and 500 mg Metformin as FDC—0/21 (0%)3/21 (14.3%)
12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets—0/23 (0%)6/23 (26.1%)
5 mg Empagliflozin and 500 mg Metformin as FDC—0/23 (0%)3/23 (13%)
5 mg Empagliflozin and 500 mg Metformin as Single Tablets—0/20 (0%)2/20 (10%)
Most frequent other events
Most frequent other events
Event12.5 mg Empagliflozin and 500 mg Metformin as FDC12.5 mg Empagliflozin and 500 mg Metformin as Single Tablets5 mg Empagliflozin and 500 mg Metformin as FDC5 mg Empagliflozin and 500 mg Metformin as Single Tablets
HeadacheNervous system disorders2/213/232/230/20
DiarrhoeaGastrointestinal disorders1/212/232/232/20
NauseaGastrointestinal disorders0/212/231/230/20
VomitingGastrointestinal disorders0/212/230/230/20

Baseline characteristics

Treated set, included all subjects that entered the study and had taken at least 1 dose of trial medication.

Age, Continuous
Age, Continuous(years)FDC Empa12.5/ Empa12.5+Met500/ FDC Empa5/ Empa5+Met500Empa12.5+Met500/ FDC Empa12.5/ Empa5+Met500/ FDC Empa5FDC Empa5/ Empa5+Met500/ FDC Empa12.5/ Empa12.5+Met500Empa5+Met500/ FDC Empa5/ Empa12.5+Met500/ FDC Empa12.5Total
Mean38.2 ± 8.630.8 ± 7.635.8 ± 10.537.5 ± 9.035.6 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)FDC Empa12.5/ Empa12.5+Met500/ FDC Empa5/ Empa5+Met500Empa12.5+Met500/ FDC Empa12.5/ Empa5+Met500/ FDC Empa5FDC Empa5/ Empa5+Met500/ FDC Empa12.5/ Empa12.5+Met500Empa5+Met500/ FDC Empa5/ Empa12.5+Met500/ FDC Empa12.5Total
Female524415
Male14229
08

Study locations

1 site
  • 1276.6.1 Boehringer Ingelheim Investigational Site
    Biberach, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2013
First posted
May 1, 2013
Start
Apr 2013
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Jul 27, 2015
Last update
Jul 27, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01844531
Responsible party
Sponsor
First posted
May 1, 2013
Start date
Apr 2013
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Jul 27, 2015
Last update
Jul 27, 2015

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin

Start the discussion